Skip to market wire
InvestLog
← Back to Stock Events← 返回个股快讯
BMYEarnings Release财报快讯Media source媒体来源Source link原始来源by InvestLog AIInvestLog AI 整理
Event time: 事件时间：
Published: 文章发布：

BMY earnings release — EPS beat +22.7% · revenue beat +2.7%百时美施贵宝 (BMY) 财报发布 — EPS 高于预期+22.7% · 营收 高于预期+2.7%

Key Results

Actual vs Consensus

  • EPS: $1.35 vs $1.10 estimate, beat+22.7%.
  • Revenue: $13.1B vs $12.7B estimate, beat+2.7%.

    • Profitability and Cash Flow

  • Period: 2026 Q3 period ended 2026-09-30
  • Revenue: $13.1B; YoY: +6.9%; QoQ: +0.7%
  • Net income: $2.2B; GAAP diluted EPS: $1.05; YoY: -1.8%; QoQ: -34.8%
  • Cash: $9.6B; Total debt: -$42.9B; Net cash: $52.5B

    • Official release: Bristol Myers Squibb Reports Third Quarter Financial Results for 2026

    核心结果

    实际值与市场预期

  • EPS：$1.35 vs $1.10 预期，高于预期+22.7%。
  • 营收：$13.1B vs $12.7B 预期，高于预期+2.7%。

    • 财务指标

  • 期间：2026 Q3（截至 2026-09-30）
  • 营收：$13.1B；同比：+6.9%；环比：+0.7%
  • 净利润：$2.2B；GAAP 稀释 EPS：$1.05；同比：-1.8%；环比：-34.8%
  • 现金：$9.6B；总债务：-$42.9B；净现金：$52.5B
    • View BMY stock details ->查看 BMY 个股详情 ->

    For information only. Not investment advice.内容仅供参考，不构成投资建议。

    Related articles相关阅读

    Bristol-Myers Squibb Company (BMY) rises 4.69% to $61.59Bristol-Myers Squibb Company（BMY）上涨 4.69%，报 $61.59

    Stock Price Move · October 20, 2026个股行情异动 · 2026/10/20

    BMY clinical outcome: Bristol Myers Squibb Announces Phase 3 ALOFT-IPF Trial Evaluating Admilparant in Adults with Idiopathic Pulmonary Fibrosis Met Primary EndpointBristol-Myers Squibb Company（BMY）披露关键临床试验达到主要终点

    Material Company Event · October 12, 2026公司公告 · 2026/10/12

    Cantor Fitzgerald lowers BMY target to $53 from $59Cantor Fitzgerald 下调目标价 施贵宝 (BMY)：$59 → $53

    Rating Change · October 8, 2026评级变动 · 2026/10/8